CARM1 and neoplasm: In view of the fact that inhibition of CARM1 induces beneficial antitumor activity in cytotoxic T cells and tumor cells, the combination of the CARM1 inhibitor EZM2302 and anti‐PD‐1 has been shown to be mutually reinforcing in strengthening ferroptosis and promoting immunotherapeutic efficacy, and the combined effect is significantly better than that of each molecule alone.